[CAS NO. 1342820-51-2] SGD-1910
PRODUCTS SPECIFICATIONS [1342820-51-2]
DESCRIPTION [1342820-51-2]
Overview
| MDL | MFCD28398131 |
|---|---|
| Molecular Weight | 1089.20 |
| Molecular Formula | C60H64N8O12 |
| SMILES | O=C(C1=CC(OC)=C(OCCCOC(C=C(N=C[C@@]2([H])N(C=C(C3=CC=C(OC)C=C3)C2)C4=O)C4=C5)=C5OC)C=C1N=C6)N7[C@@]6([H])CC(C8=CC=C(NC([C@H](C)NC([C@H](C(C)C)NC(CCCCCN(C9=O)C(C=C9)=O)=O)=O)=O)C=C8)=C7 |
Summary
SGD-1910 is a drug-linker conjugate for ADC by using the antitumor antibiotic , pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala [1] .
IC50 & Target
|
Pyrrolobenzodiazepines |
In Vitro
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
References
- [1] John A Hartley. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2020 Jun 16;1-13.
- [2] Jeffrey SC, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013 Jul 17;24(7):1256-63.
